skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Human myometrial adrenergic receptors during pregnancy: identification of the alpha-adrenergic receptor by (/sup 3/H) dihydroergocryptine binding

Journal Article · · Am. J. Obstet. Gynecol.; (United States)

The radioactive alpha-adrenergic antagonist (/sup 3/H) dihydroergocryptine binds to particulate preparations of term pregnant human myometrium in a manner compatible with binding to the alpha-adrenergic receptor (alpha-receptor). (/sup 3/H) Dihydroergocryptine binds with high affinity (KD = 2 nmol/L and low capacity (receptor concentration = 100 fmol/mg of protein). Adrenergic agonists compete for (/sup 3/H) dihydroergocryptine binding sites stereo-selectively ((-)-norepinephrine is 100 times as potent as (+)-norepinephrine) and in a manner compatible with alpha-adrenergic potencies (epinephrine approximately equal to norepinephrine much greater than isoproterenol). Studies in which prazosin, an alpha 1-antagonist, and yohimbine, and alpha 2-antagonist, competed for (/sup 3/H) dihydroergocryptine binding sites in human myometrium indicated that approximately 70% are alpha 2-receptors and that 30% are alpha 1-receptors. (/sup 3/H) dihydroergocryptine binding to human myometrial membrane particulate provides an important tool with which to study the molecular mechanisms of uterine alpha-adrenergic response.

Research Organization:
Univ. of California, San Francisco
OSTI ID:
5098425
Journal Information:
Am. J. Obstet. Gynecol.; (United States), Journal Name: Am. J. Obstet. Gynecol.; (United States)
Country of Publication:
United States
Language:
English